Photo of Bishal Gyawali from oncology.queensu.ca
Jul 18, 2023, 20:06
I argue that crossover should not be “allowed”- they should either be “mandated” or “prohibited” – Bishal Gyawali
Hot off the press in NatureRevClinOncol! Using examples from trials presented at ASCO23, in this educational piece, I highlight how we should think about crossover in cancer clinical trials. Such education also forms a core theme of what we do Common Sense Oncology. In this piece, I argue that crossover should not be “allowed”- they should either be “mandated” or “prohibited”.
For article : Click here
Source: Bishal Gyawali/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 16, 2024, 12:06
Nov 16, 2024, 11:59
Nov 16, 2024, 11:50
Nov 16, 2024, 11:47
Nov 16, 2024, 11:40
Nov 16, 2024, 11:35
Nov 16, 2024, 11:32